Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferase

Khoa A. Nguyen, Himalaya Patel, David A. Haggstrom, Alan J. Zillich, Thomas F. Imperiale, Alissa L. Russ

Research output: Contribution to journalArticle

Abstract

Background: A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However, the PGx-CDS user interface may introduce errors and promote alert fatigue. The objective of this study was to develop and evaluate a prototype of a PGx-CDS user interface for thiopurine medications with user-centered design methods. Methods: This study had two phases: In phase I, we conducted qualitative interviews to assess providers' information needs. Interview transcripts were analyzed through a combination of inductive and deductive qualitative analysis to develop design requirements for a PGx-CDS user interface. Using these requirements, we developed a user interface prototype and evaluated its usability (phase II). Results: In total, 14 providers participated: 10 were interviewed in phase I, and seven providers completed usability testing in phase II (3 providers participated in both phases). Most (90%) participants were interested in PGx-CDS systems to help improve medication efficacy and patient safety. Interviews yielded 11 themes sorted into two main categories: 1) health care providers' views on PGx-CDS and 2) important design features for PGx-CDS. We organized these findings into guidance for PGx-CDS content and display. Usability testing of the PGx-CDS prototype showed high provider satisfaction. Conclusion: This is one of the first studies to utilize a user-centered design approach to develop and assess a PGx-CDS interface prototype for Thiopurine Methyltransferase (TPMT). This study provides guidance for the development of a PGx-CDS, and particularly for biomarkers such as TPMT.

Original languageEnglish (US)
Article number194
JournalBMC medical informatics and decision making
Volume19
Issue number1
DOIs
StatePublished - Oct 17 2019

Fingerprint

thiopurine methyltransferase
Clinical Decision Support Systems
Pharmacogenetics
Interviews
Patient Safety
Health Personnel
Fatigue
Biomarkers
Physicians

Keywords

  • Clinical decision support
  • Formative evaluation
  • Pharmacogenomics
  • TPMT
  • User-centered approach

ASJC Scopus subject areas

  • Health Policy
  • Health Informatics

Cite this

Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferase. / Nguyen, Khoa A.; Patel, Himalaya; Haggstrom, David A.; Zillich, Alan J.; Imperiale, Thomas F.; Russ, Alissa L.

In: BMC medical informatics and decision making, Vol. 19, No. 1, 194, 17.10.2019.

Research output: Contribution to journalArticle

@article{fdd14cab251e434ea0adaa820637eb57,
title = "Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferase",
abstract = "Background: A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However, the PGx-CDS user interface may introduce errors and promote alert fatigue. The objective of this study was to develop and evaluate a prototype of a PGx-CDS user interface for thiopurine medications with user-centered design methods. Methods: This study had two phases: In phase I, we conducted qualitative interviews to assess providers' information needs. Interview transcripts were analyzed through a combination of inductive and deductive qualitative analysis to develop design requirements for a PGx-CDS user interface. Using these requirements, we developed a user interface prototype and evaluated its usability (phase II). Results: In total, 14 providers participated: 10 were interviewed in phase I, and seven providers completed usability testing in phase II (3 providers participated in both phases). Most (90{\%}) participants were interested in PGx-CDS systems to help improve medication efficacy and patient safety. Interviews yielded 11 themes sorted into two main categories: 1) health care providers' views on PGx-CDS and 2) important design features for PGx-CDS. We organized these findings into guidance for PGx-CDS content and display. Usability testing of the PGx-CDS prototype showed high provider satisfaction. Conclusion: This is one of the first studies to utilize a user-centered design approach to develop and assess a PGx-CDS interface prototype for Thiopurine Methyltransferase (TPMT). This study provides guidance for the development of a PGx-CDS, and particularly for biomarkers such as TPMT.",
keywords = "Clinical decision support, Formative evaluation, Pharmacogenomics, TPMT, User-centered approach",
author = "Nguyen, {Khoa A.} and Himalaya Patel and Haggstrom, {David A.} and Zillich, {Alan J.} and Imperiale, {Thomas F.} and Russ, {Alissa L.}",
year = "2019",
month = "10",
day = "17",
doi = "10.1186/s12911-019-0919-4",
language = "English (US)",
volume = "19",
journal = "BMC Medical Informatics and Decision Making",
issn = "1472-6947",
publisher = "BioMed Central",
number = "1",

}

TY - JOUR

T1 - Utilizing a user-centered approach to develop and assess pharmacogenomic clinical decision support for thiopurine methyltransferase

AU - Nguyen, Khoa A.

AU - Patel, Himalaya

AU - Haggstrom, David A.

AU - Zillich, Alan J.

AU - Imperiale, Thomas F.

AU - Russ, Alissa L.

PY - 2019/10/17

Y1 - 2019/10/17

N2 - Background: A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However, the PGx-CDS user interface may introduce errors and promote alert fatigue. The objective of this study was to develop and evaluate a prototype of a PGx-CDS user interface for thiopurine medications with user-centered design methods. Methods: This study had two phases: In phase I, we conducted qualitative interviews to assess providers' information needs. Interview transcripts were analyzed through a combination of inductive and deductive qualitative analysis to develop design requirements for a PGx-CDS user interface. Using these requirements, we developed a user interface prototype and evaluated its usability (phase II). Results: In total, 14 providers participated: 10 were interviewed in phase I, and seven providers completed usability testing in phase II (3 providers participated in both phases). Most (90%) participants were interested in PGx-CDS systems to help improve medication efficacy and patient safety. Interviews yielded 11 themes sorted into two main categories: 1) health care providers' views on PGx-CDS and 2) important design features for PGx-CDS. We organized these findings into guidance for PGx-CDS content and display. Usability testing of the PGx-CDS prototype showed high provider satisfaction. Conclusion: This is one of the first studies to utilize a user-centered design approach to develop and assess a PGx-CDS interface prototype for Thiopurine Methyltransferase (TPMT). This study provides guidance for the development of a PGx-CDS, and particularly for biomarkers such as TPMT.

AB - Background: A pharmacogenomic clinical decision support tool (PGx-CDS) for thiopurine medications can help physicians incorporate pharmacogenomic results into prescribing decisions by providing up-to-date, real-time decision support. However, the PGx-CDS user interface may introduce errors and promote alert fatigue. The objective of this study was to develop and evaluate a prototype of a PGx-CDS user interface for thiopurine medications with user-centered design methods. Methods: This study had two phases: In phase I, we conducted qualitative interviews to assess providers' information needs. Interview transcripts were analyzed through a combination of inductive and deductive qualitative analysis to develop design requirements for a PGx-CDS user interface. Using these requirements, we developed a user interface prototype and evaluated its usability (phase II). Results: In total, 14 providers participated: 10 were interviewed in phase I, and seven providers completed usability testing in phase II (3 providers participated in both phases). Most (90%) participants were interested in PGx-CDS systems to help improve medication efficacy and patient safety. Interviews yielded 11 themes sorted into two main categories: 1) health care providers' views on PGx-CDS and 2) important design features for PGx-CDS. We organized these findings into guidance for PGx-CDS content and display. Usability testing of the PGx-CDS prototype showed high provider satisfaction. Conclusion: This is one of the first studies to utilize a user-centered design approach to develop and assess a PGx-CDS interface prototype for Thiopurine Methyltransferase (TPMT). This study provides guidance for the development of a PGx-CDS, and particularly for biomarkers such as TPMT.

KW - Clinical decision support

KW - Formative evaluation

KW - Pharmacogenomics

KW - TPMT

KW - User-centered approach

UR - http://www.scopus.com/inward/record.url?scp=85073551967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85073551967&partnerID=8YFLogxK

U2 - 10.1186/s12911-019-0919-4

DO - 10.1186/s12911-019-0919-4

M3 - Article

C2 - 31623616

AN - SCOPUS:85073551967

VL - 19

JO - BMC Medical Informatics and Decision Making

JF - BMC Medical Informatics and Decision Making

SN - 1472-6947

IS - 1

M1 - 194

ER -